Goose egg addling

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, GLOBE, R, ABOS, SEC, Clinical trial, Board, Security (finance), Knowledge, Research, Marketing, Patient, Eli Lilly, SAD, G&A, Employment, NCT, Neuron, Cash balance plan, Safety, Neurodegeneration, Pathology, Conference, CMC, Pharmacokinetics, Forward-looking statement, MS, Poster, MAD, Eli Lilly and Company, Therapy, COVID-19, Program, PK, AD, Head, Goal, Neurotoxin, FDA, Private Securities Litigation Reform Act, Novavax, Mab, Goose egg addling, Research and development, Company, Fermentation, VP, NASDAQ, Neuroscience, Insurance, Administration, Pharmaceutical industry, Cryptocurrency, Vaccine, Chemistry, Acumen

We remain on track to report topline results in the first half of 2023, said Daniel OConnell, President and Chief Executive Officer of Acumen.

Key Points: 
  • We remain on track to report topline results in the first half of 2023, said Daniel OConnell, President and Chief Executive Officer of Acumen.
  • Acumen anticipates initiating a Phase 2/3 trial for ACU193 following completion of INTERCEPT-AD, if successful, and subsequent consultation and feedback from the FDA.
  • We thank Jeff for his service and support of Acumen over the last three years, said Dan OConnell, Chief Executive Officer of Acumen.
  • Acumen will host a conference call and live audio webcast today, August 15, 2022, at 4:30 pm ET.

Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease

Retrieved on: 
Monday, August 1, 2022
Private Securities Litigation Reform Act, Goal, Pathology, AAIC, Brain, Knowledge, GLOBE, U.S. Securities and Exchange Commission, SEC, Research, ABOS, Safety, Instability, NASDAQ, Conference, Goose egg addling, AD, Security (finance), Patient, Poster, Therapy, Pharmaceutical industry, Vaccine, Acumen

Utilizing A-derived diffusible ligands (ADDLs) as a synthetic AO model may aid in standardization of AO assays.

Key Points: 
  • Utilizing A-derived diffusible ligands (ADDLs) as a synthetic AO model may aid in standardization of AO assays.
  • For example, using ADDL assays to better understand the specificity and selectivity of A-targeting antibodies may support therapeutic development.
  • Acumens scientific founders pioneered research on AOs, which a growing body of evidence indicates are primary triggers of Alzheimers disease pathology.
  • Additional information will be made available in other filings that Acumen makes from time to time with the SEC.